ZYBERNO
Stock Report
Updated Aug 31, 2026

Fractyl Health, Inc. (GUTS)

Healthcare • NASDAQ

$0.70

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
10.0/100
POOR BUSINESS
Fractyl Health, Inc. (GUTS) scores 10/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-1,625.9%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-184.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Fractyl Health, Inc. (GUTS) stock report — Zyberno Score 10/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, GUTS generated -$90.73M in Owner Earnings. Capital was deployed as follows: $557.00K invested in capital expenditures. Reinvestment rate: 0.9%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.70
Market Cap:$111.69M

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$94.84M

Price Action & Momentum (1)

% of 52-Week High:28.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-101.3%
Reinvestment Rate:0.9%
Fundamental Growth Rate (g):-1.6%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$135.95
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.15x
Quick Ratio:3.15x
Cash Ratio:3.00x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:33,866,000.00
Cash And Cash Equivalents:47,140,000.00
Long Term Debt:$25.11M
Net Debt:-$16.85M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $0.00
Linear Growth: -50.0%
📊 Click to view full GUTS Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

Gross profit TTM: $43.00K
Linear Growth: -6.5%
📊 Click to view full GUTS Gross Profit analysis & methodology →
-$85.89M

Bottom Line Performance (3)

-$105.65M
Income Before Tax:$0.00
Ebitda Ttm:-84,774,000.00

Operating Expenses (5)

Operating Expenses:85,894,000.00
R And D Expense:63,360,000.00
Sga Expense:22,534,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$81.98M
Current Assets:$49.60M
Ppe Net:1,848,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:83,641,000.00
Current Liabilities:15,736,000.00
Long Term Debt:$25.11M
Short Term Debt:$5.18M

Equity & Capital (3)

Equity:-$1.67M
Retained Earnings:-$572.58M
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:73,000.00
Accounts Payable:1,006,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,496,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$87.73M-$88.28M

Investment Activities (2)

Investing Cash Flow:-$3.00K
Capital Expenditures Ttm:557,000.00

Financing Activities (3)

Financing Cash Flow:$4.11M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:170,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:1,120,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.90
-$0.90
Earnings Per Share Ttm:-$0.67

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.57

Book Value & Capital (2)

Book Value Per Share:-$0.01
Cash Per Share:0.30

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$90.73M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.9%
Fundamental Growth Rate (g):-1.6%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-50.0%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-6.5%
Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:GUTS
Company Name:Fractyl Health, Inc.
Sector:Healthcare
Industry:Medical Devices
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:158.65M
Shares Outstanding Basic:158.65M
Shares Outstanding Diluted:158.65M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 17:16:28 UTC
Data Timestamp:2026-08-19T15:28:43.498437
Scroll to Top